NRX Pharmaceuticals, Inc.

Good morning, everyone, and welcome to the NRX Pharmaceuticals, Inc. fourth quarter and full year 2023 results conference call. Currently, all participants are in a listen-only mode. As a reminder, this conference call is being recorded. I will now turn the call over to Matthew Duffy, the company's chief business officer. Please go ahead.

Thank you, Camilla, and welcome, everyone.

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof. and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the pre-announced press release issued Thursday, the company's Form 10-K filed Friday, and the press release issued this morning, all of which may be accessed from the investor page of the NRX Pharmaceuticals website. Joining me today are Jonathan Javitt, our Chairman and Chief Scientist, Stephen Willard, Chief Executive Officer, and Richard Dorito, Chief Financial Officer and Treasurer. Jonathan and Stephen will provide a summary of the company's progress. Rich will review the company's financial results, and then Jonathan will review upcoming milestones before making closing comments. Following their prepared remarks, we will address investor questions. I will now turn the call over to Jonathan. Jonathan?